Skip to main content
SpringerLink
Log in

Cytoreductive Surgery and “Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”

  • Chapter
  • First Online:
Induction Chemotherapy

  • 903 Accesses

Abstract

For a long time malignant tumor manifestation of the peritoneum, peritoneal carcinomatosis (PC) was regarded as terminal. This meant that both medical and surgical palliation treatments came into question which aimed to keep quality of life as long as possible. These methods are known as “best supportive care.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Bauliuex J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer. 2000;15:358–63.

    Article  Google Scholar 

  2. Hardy JR, Wiltshaw E, Blake PR, Slevin M, Perren TJ, Tan S. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol. 1991;2:131–6.

    Article  CAS  PubMed  Google Scholar 

  3. Curtin JP, Malik R, Venkatramann ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9–12.

    Article  CAS  PubMed  Google Scholar 

  4. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Kuzuya K, Shiromizu K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S. Prognostic factors of stage UV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398–403.

    Article  CAS  PubMed  Google Scholar 

  5. Sampson JA. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol. 1931;7:423–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery systems for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.

    CAS  PubMed  Google Scholar 

  7. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Takahashi M, Okui K. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat. 1989;2:198–202.

    Google Scholar 

  8. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  9. Sugarbaker PH, Hughes KA. Surgery for colorectal metastasis to liver. In: Wanebo H, editor. Colorectal cancer. St. Louis: Mosby; 1993. p. 405–13.

    Google Scholar 

  10. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Brujin EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97.

    CAS  PubMed  Google Scholar 

  11. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sugarbaker PH. Observations concerning cancer spread within the peritoneal carcinomatosis: principles and management. Boston: Kluwer Academic Publ; 1996. p. 79–100.

    Google Scholar 

  13. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384:576–87.

    Article  CAS  Google Scholar 

  14. Glehen O, Mithieux F, Osinsky D, Beuajard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21:799–806.

    Article  CAS  PubMed  Google Scholar 

  15. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–6.

    Article  CAS  PubMed  Google Scholar 

  16. Glehen O, Gilly FN, Sugarbaker PH. New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? Scand J Surg. 2003;92:178–9.

    CAS  PubMed  Google Scholar 

  17. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.

    Article  CAS  PubMed  Google Scholar 

  18. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341–6.

    Article  CAS  PubMed  Google Scholar 

  19. Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–84.

    Article  CAS  PubMed  Google Scholar 

  20. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.

    Article  CAS  PubMed  Google Scholar 

  21. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;20:3737–43.

    Article  Google Scholar 

  22. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2008;15:2426–32.

    Article  PubMed  Google Scholar 

  23. Arakeljan E, Gunningberg L, Larsson J, Norlen K, Mahteme H. Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2011;37:897–903.

    Article  Google Scholar 

  24. Raspe C, Piso P, Wiesnack C, Bucher M. Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anesthesiol. 2012;25:348–55.

    Article  CAS  Google Scholar 

  25. Dawson LE, Russell AH, Tong D. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22:95–9.

    Article  CAS  PubMed  Google Scholar 

  26. Chu DZ, Lang NP, Thompson C. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–7.

    Article  CAS  PubMed  Google Scholar 

  27. Glockzin G, Ghali N, Lang SA, Schlitt HJ, Piso P. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. J Surg Oncol. 2009;100:306–10.

    Article  PubMed  Google Scholar 

  28. Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum. 1991;34:723–7.

    Article  CAS  PubMed  Google Scholar 

  29. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Esquivel J, Chua TC, Stojadinovic A, Torres Melero J, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer Index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–70.

    Article  CAS  PubMed  Google Scholar 

  31. Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98:263–7.

    Article  PubMed  Google Scholar 

  32. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of surgical Oncology. Ann Surg Oncol. 2007;14(1):128–33.

    Article  CAS  PubMed  Google Scholar 

  33. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008;98:273–6.

    Article  CAS  PubMed  Google Scholar 

  34. Gomez-Portilla A, Sugarbaker PH, Chang D. Second-look surgery after cytoreductive and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23–9.

    Article  Google Scholar 

  35. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;3:413–9.

    Article  Google Scholar 

  36. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;42:S15–25.

    Article  Google Scholar 

  37. Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20:585–92.

    Article  CAS  PubMed  Google Scholar 

  38. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.

    Article  PubMed  Google Scholar 

  39. Kusamura S, Baratti D, Antonucci A, Younan R, Laterza B, Oliva GD, Gavazzi C, Deraco M. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:3443–52.

    Article  PubMed  Google Scholar 

  40. Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2:68–75.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.

    Article  CAS  PubMed  Google Scholar 

  42. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288:F433–42.

    Article  CAS  PubMed  Google Scholar 

  43. De Lima VV, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52:108–12.

    Article  CAS  Google Scholar 

  44. El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Los G, Verdegal EM, Mutsaers PH, Mc Vie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–65.

    Article  CAS  PubMed  Google Scholar 

  46. Fujimoto S, Takahashi M, Kobayashi K, Nagano K, Kure M, Mutoh T, Ohkubo H. Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer. 1992;70:2754–60.

    Article  CAS  PubMed  Google Scholar 

  47. Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, Sayag A, Salle B, Brachet A, Bienvenu J. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology. 1993;50:366–70.

    Article  CAS  PubMed  Google Scholar 

  48. Van de Vaart PJ, Van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148–54.

    Article  PubMed  Google Scholar 

  49. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351–81.

    Article  CAS  PubMed  Google Scholar 

  50. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer. 1977;39:2637–46.

    Article  CAS  PubMed  Google Scholar 

  51. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.

    Article  PubMed  Google Scholar 

  52. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984;44:605–12.

    CAS  PubMed  Google Scholar 

  53. Benoit L, Duvillard C, Rat P, Chauffert B. The effect of intra-abdominal temperature on the tissue and tumor diffusion of intraperitoneal cisplatin in a model of peritoneal carcinomatosis in rats. Chirurgie. 1999;124:375–9.

    Article  CAS  PubMed  Google Scholar 

  54. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdijan S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.

    Article  CAS  PubMed  Google Scholar 

  55. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10:112–22.

    Article  CAS  PubMed  Google Scholar 

  56. Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J. Peritoneal carcinomatosis: intraoperative parameters in open (Coliseum) versus closed abdomen HIPEC. Int J Surg Oncol. 2015; Epub 2015 Feb 15.

    Google Scholar 

  57. Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15:216–24.

    Article  PubMed  Google Scholar 

  58. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol. 2002;9:186–91.

    Article  PubMed  Google Scholar 

  59. Schierl R, Novotna J, Piso P, Böhlandt A, Nowak D. Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2012;38:88–94.

    Article  CAS  PubMed  Google Scholar 

  60. Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J, Garnier R. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015;53:28–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Gonzalez-Bayon L, Gonzalez-Moreno S, Ortega-Perez G. Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol. 2006;32:619–24.

    Article  CAS  PubMed  Google Scholar 

  62. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum technique”. Ann Surg Oncol. 2000;7:296–300.

    Article  CAS  PubMed  Google Scholar 

  63. Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994;71:633–40.

    CAS  PubMed  Google Scholar 

  64. Morris DL, Chambers HF, Morris MG, Sande MA. Hemodynamic characteristics of patients with hypothermia due to occult infection and other causes. Ann Intern Med. 1985;102:153–7.

    Article  CAS  PubMed  Google Scholar 

  65. Seekamp A, van Griensven M, Hildebrandt F, Wahlers T, Tscherne H. Adenosine-triphosphate in trauma-related and elective hypothermia. J Trauma. 1999;47:673–83.

    Article  CAS  PubMed  Google Scholar 

  66. Kanakoudis F, Petrou A, Michaloudis D, Chortaria G, Konstantinidou A. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia. 1996;51:1033–6.

    Article  CAS  PubMed  Google Scholar 

  67. Shime N, Lee M, Hatanaka T. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. Anesth Analg. 1994;78:938–42.

    Article  CAS  PubMed  Google Scholar 

  68. Cafiero T, Di Lorio C, Di Minno RM, Sivolella G, Confuorto G. Non-invasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. Minerva Anestesiol. 2006;72:207–15.

    CAS  PubMed  Google Scholar 

  69. Schmidt C, Creutzenberg M, Piso P, Hobbahn J, Bucher M. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2008;63:389–95.

    Article  CAS  PubMed  Google Scholar 

  70. Raue W, Tsilimparis N, Bloch A, Menenakos C, Hartmann J. Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy. Eur Surg Res. 2009;43:365–72.

    Article  CAS  PubMed  Google Scholar 

  71. Vorgias G, Iavazzo C, Mavromatis J, Leontara J, Katsoulis M, Kalinoglou N, Akrivos T. Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol. 2007;14:1919–23.

    Article  PubMed  Google Scholar 

  72. De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, Mortier E. Severe hyponatremia and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28:61–6.

    PubMed  Google Scholar 

  73. Raft J, Parisot M, Marchal F, Tala S, Desandes E, Lalot JM, Guillemin F, Longrois D, Meistelman C. Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance. Ann Fr Anesth Reanim. 2010;29:676–81.

    Article  CAS  PubMed  Google Scholar 

  74. Thix CA, Königsrainer I, Kind R, Wied P, Schroeder TH. Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2009;64:1134–6.

    Article  CAS  PubMed  Google Scholar 

  75. Cooksley TJ, Haji-Michael P. Postoperative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2011;9:169.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Synder G, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010;105:106–15.

    Article  Google Scholar 

  77. De la Chapelle A, Perus O, Soubielle J, Raucoulles-Aime M, Bernard JL, Bereder JM. High potential for epidural analgesia neuraxial block-associated hypotension in conjunction with heated intraoperative intraperitoneal chemotherapy. Reg Anaesthesiol Pain Med. 2005;30:313–4.

    Article  Google Scholar 

  78. Desgranges FP, Steghens A, Rosay H, Méeus P, Stoian A, Daunizeau AL, Pouderoux-Martin S, Piriou V. Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique ? Ann Fr Anesth Reanim. 2012;31(1):53–9.

    Article  PubMed  Google Scholar 

  79. Desgranges FP, Steghens A, Mithieux F, Rosay H. Potential risks of thoracic epidural analgesia in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2010;101:442.

    PubMed  Google Scholar 

  80. Mann V, Mann S, Hecker A, Röhrig R, Müller M, Schwandner T, Hirschburger M, Sprengel A, Weigand MA, Padberg W. Continuous local wound infusion with local anesthetics: for thoracotomy and major abdominal interventions. Chirurg. 2011;82:906–12.

    Article  CAS  PubMed  Google Scholar 

  81. Younan R, Kusamura S, Bratti D, Cloutier AS, Deraco M. Morbidity, toxicity and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98:253–7.

    Article  PubMed  Google Scholar 

  82. Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, Pinto E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol. 2011;20:e38–54.

    Article  PubMed  Google Scholar 

  83. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehmann AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.

    Article  CAS  PubMed  Google Scholar 

  84. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, Levine EA. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:1105–13.

    Article  PubMed  Google Scholar 

  85. Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a systematic review and meta-analysis. Surg Oncol. 2014;23:199–210.

    Article  PubMed  Google Scholar 

  86. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–603.

    Article  CAS  PubMed  Google Scholar 

  87. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.

    Article  CAS  PubMed  Google Scholar 

  88. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997;145:211–8.

    Article  CAS  PubMed  Google Scholar 

  89. Peterson Jr JT, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984;54:951–60.

    Article  PubMed  Google Scholar 

  90. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  PubMed  Google Scholar 

  91. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133:1317–31.

    PubMed  Google Scholar 

  92. Antmann KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356–62.

    Article  Google Scholar 

  93. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.

    Article  CAS  PubMed  Google Scholar 

  94. Deraco M, Baratti D, Cabras AD, Zaffaroni N, Perrone F, Villa R, Jocolle J, Balestra MA, Kusamura S, Laterza B, Pilotti S. Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol. 2010;2:76–84.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systemic review and meta-analysis. Ann Surg Oncol. 2015;22:1686–93.

    Article  PubMed  Google Scholar 

  96. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.

    Article  PubMed  Google Scholar 

  97. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy ion patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416–24.

    Article  PubMed  Google Scholar 

  98. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14:1790–7.

    Article  Google Scholar 

  99. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron GF, Guilloit JM, Meeus P, Goere D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2008;27:681–5.

    Article  PubMed  Google Scholar 

  100. Verwaal VJ, Van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65–71.

    Article  PubMed  Google Scholar 

  101. Da Silva GR, Cabanas J, Sugarbaker PH. Limited survival in the treatment of carcinomatosis from rectal cancer. Dis Colon Rectum. 2005;48:2258–63.

    Article  Google Scholar 

  102. Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9–15.

    Article  PubMed  Google Scholar 

  103. Van Ouheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, Van Ramshorst B, Luyer P, De Hingh ICH. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111:237–42.

    Article  Google Scholar 

  104. Elias D, Goerer D, di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, Dromain C, Ducreux M. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445–50.

    Article  PubMed  Google Scholar 

  105. Moran BJ, Cecil TD. The etiology, clinical presentation and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585–603.

    Article  PubMed  Google Scholar 

  106. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.

    Article  PubMed  Google Scholar 

  107. Weaver CH. Mucocele of the appendix with pseudomucinous degeneration. Am J Surg. 1937;36:523–6.

    Article  Google Scholar 

  108. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19:1390–408.

    Article  CAS  PubMed  Google Scholar 

  109. Szych C, Staebler A, Connoly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Carr NJ, Emory TS, Sobin LH. Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation apoptosis and expression of p53, CD44, bcl-2. Arch Pathol Lab Med. 2002;126:837–41.

    CAS  PubMed  Google Scholar 

  111. Kahn MA, Demopoulos RI. Mucinous ovarian tumors with pseudomyxoma peritonei: a clinicopathological study. Int J Gynecol Pathol. 1992;11:15–23.

    Article  CAS  PubMed  Google Scholar 

  112. Chejfec G, Rieker WJ, Jablokow VR, Gould VE. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986;90:202–5.

    CAS  PubMed  Google Scholar 

  113. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, van Heerden JA. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Am Surg. 1994;219:112–9.

    CAS  Google Scholar 

  114. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Gonzaelz-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304–11.

    Article  Google Scholar 

  116. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98:277–82.

    Article  PubMed  Google Scholar 

  117. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gomez-Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, Gonzalez-Moreno S, Van der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.

    Google Scholar 

  118. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality and morbidity. J Surg Oncol. 2011;104:692–8.

    Article  PubMed  Google Scholar 

  119. Ikeguchi M, Oka A, Tsujitani S, Maeta M, Kaibara N. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res. 1994;14:2131–4.

    CAS  PubMed  Google Scholar 

  120. Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131–8.

    Article  CAS  PubMed  Google Scholar 

  121. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.

    Article  CAS  PubMed  Google Scholar 

  122. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004.

    Article  CAS  PubMed  Google Scholar 

  123. Kochi M, Fujii M, Kanamori N, Kaiga T, Takahashi T, Kobayashi M, Takayama T. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. J Cancer Res Clin Oncol. 2006;132:781–5.

    Article  CAS  PubMed  Google Scholar 

  124. Yabusaki Y, Nashimoto A, Tanaka O. Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer. Jpn J Cancer Chemother. 2003;30:1933–40.

    Google Scholar 

  125. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6:45–9.

    Google Scholar 

  126. Swellengrebel HA, Zoetmulder FA, Smeenk RM, Antonini N, Verwaal VJ. Quantitative intra-operative assessment of peritoneal carcinomatosis – a comparison of three prognostic tools. Eur J Surg Oncol. 2009;35:1078–84.

    Article  CAS  PubMed  Google Scholar 

  127. Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101:459–64.

    Google Scholar 

  128. Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85–97.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702–13.

    Article  PubMed  Google Scholar 

  130. Di Vita M, Capellani A, Piccolo G, Zanghi A, Cavallaro A, Bertola G, Bolognese A, Facchini G, D’Aniello C, Di Francia R, Cardi F, Berretta M. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anti Cancer Drugs. 2015;26:123–38.

    Article  PubMed  CAS  Google Scholar 

  131. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.

    Article  PubMed  Google Scholar 

  132. Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100:311–6.

    Article  CAS  PubMed  Google Scholar 

  133. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.

    Article  PubMed  Google Scholar 

  134. Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32:625–7.

    Article  PubMed  Google Scholar 

  135. Yano M, Shiozaki H, Inoue M, Tamura S, Doki Y, Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. Worl J Surg. 2002;26:1155–9.

    Article  Google Scholar 

  136. Yonemura Y, Shinbo M, Hagiwara A. Treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Gastroenterol Surg. 2008;31:802–12.

    Google Scholar 

  137. Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, Sugarbaker PH. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661–5.

    Article  CAS  PubMed  Google Scholar 

  138. Siegel R, Naishadham R, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  139. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75.

    Article  CAS  PubMed  Google Scholar 

  140. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  CAS  PubMed  Google Scholar 

  141. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15:3–11.

    Article  PubMed  Google Scholar 

  142. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  CAS  PubMed  Google Scholar 

  143. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637–45.

    Article  PubMed  Google Scholar 

  144. Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macri A, Virzi S, Puccio F, Ravenda PS, Kusamura S. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37:4–9.

    Article  CAS  PubMed  Google Scholar 

  145. Winter 3rd WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26:83–9.

    Article  PubMed  Google Scholar 

  146. Roviello F, Roviello G, Petrioli R, Marrelli D. Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: a brief overview of recent results. Crit Rev Oncol Hematol. 2015;11 Epub ahead of print.

    Google Scholar 

  147. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Morice P, Pomel C, Pocard M, Guyon F, Porcheron J, Glehen O, FROGHI (French Oncologic and Gynecologic HIPEC) Group. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicenter retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43.

    Article  CAS  PubMed  Google Scholar 

  148. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efsthatiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–5.

    Article  CAS  PubMed  Google Scholar 

  149. OVIHIPEC trial; ClinicalTrials.gov identifier:NCT00426257.http://clinicaltrials.gov/ct2/show/NCT00426257.

  150. Chua TC, Liauw W, Robertson G, Chia WK, Soo KC, Alobaid A, Al-Mohaimeed K, Morris DL. Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol. 2009;114:137–9.

    Article  PubMed  Google Scholar 

  151. Classe JM, Muller M, Frenel JS, Berton Rigaud D, Ferron G, Jaffré I, Gladieff L. Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. J Gynecol Obstet Biol Reprod. 2010;39:183–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemein-, Viszeral-, Thorax-, Transplantations- u. Kinderchirurgie, Universitätsklinikum Gießen, Rudolf-Buchheim-Straße 7, Gießen, 35385, Germany

    Markus Hirschburger & Winfried Padberg

Authors
  1. Markus Hirschburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Winfried Padberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Hirschburger .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, Medias Klinikum GmbH & Co KG, Burghausen, Germany

    Karl Reinhard Aigner

  2. Royal Prince Alfred, Sydney Hospitals, Mosman, New South Wales, Australia

    Frederick O. Stephens

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hirschburger, M., Padberg, W. (2016). Cytoreductive Surgery and “Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”. In: Aigner, K., Stephens, F. (eds) Induction Chemotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-28773-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28773-7_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28771-3

  • Online ISBN: 978-3-319-28773-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation